Meeting
2013 ASCO Annual Meeting
An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).
Authors
Jeffrey Alan Sosman
Vanderbilt-Ingram Cancer Center, Nashville, TN
Jeffrey Alan Sosman , Salvador Martin-Algarra , Jedd D. Wolchok , William Howard Sharfman , Shailender Bhatia , F. Stephen Hodi , Wen-Jen Hwu , Thomas Gajewski , Craig L. Slingluff Jr., Howard Kaufman , Manish Gupta , Analia McGirr , Christine E. Horak , Christoph Matthias Ahlers , Jon M. Wigginton , Walter John Urba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01621490
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS3114)
DOI
10.1200/jco.2013.31.15_suppl.tps3114
Abstract #
TPS3114
Poster Bd #
23A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde
Poster
2013 ASCO Annual Meeting
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
First Author: Bartosz Chmielowski